In summary, saroglitazar attenuates pulmonary fibrosis by suppressing macrophage-driven inflammation via NF-κB/NLRP3 inhibition and disrupting the macrophage–fibroblast crosstalk. This evidence concerns the gene NFKB1 and pulmonary fibrosis.